The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 27 ·No. 9 ·2009-03-20 ·Pages 1350-4

Langer CJ

Abstract

暂无摘要

MeSH Terms

Carcinoma, Non-Small-Cell Lung/drug therapy,enzymology,genetics ErbB Receptors/antagonists & inhibitors,genetics Gefitinib Humans Lung Neoplasms/drug therapy,enzymology,genetics Mutation Protein Kinase Inhibitors/therapeutic use Quinazolines/therapeutic use Severity of Illness Index

Chemicals

Protein Kinase Inhibitors Quinazolines ErbB Receptors Gefitinib

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Langer Corey J

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

1527-7755

DOI

10.1200/JCO.2008.20.4859

Published

2009-03-20

Epub

2009-00-17

Pages

1350-4

Language

English

Region

United States

NLM ID

8309333

Subset

Corrections

CommentOn

PMID: 19224850

External Links

PubMed source DOI: 10.1200/JCO.2008.20.4859 View journal details

Analysis Services

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

Contact

WeChat Official Account